| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/31/2014 | US20140212969 Nucleic Acids, Polypetides, and Methods for Modulating Apoptosis |
| 07/31/2014 | US20140212572 Pharmaceutical compositions for the coordinated delivery of nsaids |
| 07/31/2014 | US20140212524 Methods and compositions to reduce fat gain, promote weight loss in mammals |
| 07/31/2014 | US20140212523 Methods and compositions to reduce fat gain, promote weight loss in mammals |
| 07/31/2014 | US20140212522 Methods and compositions to reduce fat gain, promote weight loss in mammals |
| 07/31/2014 | US20140212521 Methods and compositions to reduce fat gain, promote weight loss in mammals |
| 07/31/2014 | US20140212515 Composition and methods for optimizing health of cancer patients by the administration of sodium selenite and vitamin k3 |
| 07/31/2014 | US20140212514 Prevention of gastric ulcer by carbon monoxide |
| 07/31/2014 | US20140212509 Inhibitors of poly(adp-ribose)polymerase |
| 07/31/2014 | US20140212506 Method to Suppress the Systemic Toxicity of Chemotherapeutic Drugs |
| 07/31/2014 | US20140212504 Phospholipid-based powders for drug delivery |
| 07/31/2014 | US20140212503 Delivery system |
| 07/31/2014 | US20140212501 Compositions of lopinavir |
| 07/31/2014 | US20140212498 Oil-in-water emulsions that contain nucleic acids |
| 07/31/2014 | US20140212496 New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| 07/31/2014 | US20140212495 Nanoparticulate compositions of tubulin inhibitor compounds |
| 07/31/2014 | US20140212494 Methods of Improving Digestive Health |
| 07/31/2014 | US20140212493 Highly Bioavailable Composition Containing Eprosartan - Poloxamer Complex or 2-(7-Chloro-5-Methyl-4-Oxo-3-Phenyl-4,5-Dihydro-3H-Pyridazine (4,5-b)Indol-1-yl)-N,N-Dimethylacetamide - Poloxamer Complex |
| 07/31/2014 | US20140212491 Combination formulation of two antiviral compounds |
| 07/31/2014 | US20140212490 Tablet for pulsed delivery |
| 07/31/2014 | US20140212489 Pharmaceutical compositions for the coordinated delivery of nsaids |
| 07/31/2014 | US20140212488 Oral tablet formulation consisting of immediate release rosuvastatin and extended release metformin |
| 07/31/2014 | US20140212487 Solid dispersion formulation of an antiviral compound |
| 07/31/2014 | US20140212486 Isometheptene isomer |
| 07/31/2014 | US20140212485 Inhibitors of bruton's tyrosine kinase |
| 07/31/2014 | US20140212483 Compositions for Treatment of Attention Deficit Hyperactivity Disorder |
| 07/31/2014 | US20140212480 Ceramide anionic liposome compositions |
| 07/31/2014 | US20140212479 Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers |
| 07/31/2014 | US20140212478 Method for preventing and/or treating periodontal disease |
| 07/31/2014 | US20140212476 Method of Targeting Hydrophobic Drugs to Vascular Lesions |
| 07/31/2014 | US20140212475 Anti-cancer compositions and methods |
| 07/31/2014 | US20140212474 Drug carriers |
| 07/31/2014 | US20140212463 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
| 07/31/2014 | US20140212462 POLYMER NANOPARTICLE INJECTION FORMULATION COMPOSITION CONTAINING RAPAMYCIN WITH IMPROVED WATER SOLUBILITY, PREPARATION METHOD THEREOF, AND ANTICANCER COMPOSITION FOR COMBINED USE WITH RADIOTHERAPY (as amended) |
| 07/31/2014 | US20140212461 Methods for Treatment of Attention Deficit Hyperactivity Disorder |
| 07/31/2014 | US20140212460 Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures |
| 07/31/2014 | US20140212453 Snack system, including interior filing of ingredient, outer coating of ingredient, addition of ingredient, and formation of snack roll |
| 07/31/2014 | US20140212437 Methods and compositions for treating atrial fibrillation |
| 07/31/2014 | US20140212414 Combination therapy using p53 activator and c-met inhibitor |
| 07/31/2014 | US20140212413 Methods of Treating TNF-alpha-Mediated Diseases Using Chimeric TNF-alpha Antibodies |
| 07/31/2014 | US20140212411 Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| 07/31/2014 | US20140212410 Co-administration of eribulin and farletuzumab for the treatment of breast cancer |
| 07/31/2014 | US20140212407 Treatment of obesity |
| 07/31/2014 | US20140212402 Method of stabilizing reduced coenzyme q10 |
| 07/31/2014 | US20140212396 Compositions and methods for treatment of cancer using bacteria |
| 07/31/2014 | US20140212388 Composition For Cosmetic And Health Improvement |
| 07/31/2014 | US20140212384 Therapeutic Methods |
| 07/31/2014 | US20140212382 Purine monophosphate prodrugs for treatment of viral infections |
| 07/31/2014 | US20140212373 Multi-Vinylsulfone Containing Molecule |
| 07/31/2014 | US20140212372 Hydrogels comprising crosslinked polymers containing biomass derived materials |
| 07/31/2014 | US20140212370 Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same |
| 07/31/2014 | US20140212362 Composition and method for treatment of symptoms associated with various skin conditions |
| 07/31/2014 | US20140210117 Pharmaceutical compositions of dispersions of drug and neutral polymers |
| 07/31/2014 | US20140209461 Poly and Copoly(N-vinylamide)s and Their Use In Capillary Electrophoresis |
| 07/31/2014 | US20140209100 Intravaginal devices for drug delivery |
| 07/31/2014 | DE112012002748T5 Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon Method for the treatment of HCV comprising at least two direct-acting antiviral agents, interferon ribavirin but not |
| 07/31/2014 | DE102013001636A1 Pharmazeutische Zusammensetzung umfassend Leflunomid A pharmaceutical composition comprising leflunomide |
| 07/30/2014 | EP2759596A1 Short interfering ribonucleic acid (siRNA) |
| 07/30/2014 | EP2759595A1 Composition comprising an encapsulated antagomir |
| 07/30/2014 | EP2759547A1 Platinum compound having amino- or alkylamino-containing succinic acid derivatives as leaving group, preparation method therefor, and use thereof |
| 07/30/2014 | EP2759544A1 Compounds having antiviral properties |
| 07/30/2014 | EP2759540A2 Beta-3 receptor ligands and their use in therapy |
| 07/30/2014 | EP2759536A1 Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents |
| 07/30/2014 | EP2759533A1 Condensed heterocyclic compound |
| 07/30/2014 | EP2759300A2 Use of a composition in the production of a dialysis solution for the treatment of cerebrovascular diseases by means of peritoneal dialysis |
| 07/30/2014 | EP2759299A1 Galactosaminogalactan comprising alpha 1-4 linked galactose and alpha 1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease |
| 07/30/2014 | EP2759298A1 Therapeutic combinations of netupitant and palonosetron |
| 07/30/2014 | EP2759297A1 Combination therapy using p53 activator and c-Met inhibitor |
| 07/30/2014 | EP2759296A1 Gip elevation inhibitor |
| 07/30/2014 | EP2759295A1 Foam cell specific Liver X Receptor (LXR) alpha agonist, SIRT1 inhibitors as well as p300 inhibitors as pharmaceutically active agents |
| 07/30/2014 | EP2759294A1 Percutaneously absorbable preparation containing fentanyl and a homologue thereof |
| 07/30/2014 | EP2759293A1 Pharmaceutical compositions of (+)-(s)-2-(3-benzoylphenyl)propionic acid tromethamine salt |
| 07/30/2014 | EP2759292A1 Dual action, inhaled formulations providing both an immediate and sustained release profile |
| 07/30/2014 | EP2758419A1 Novel betulinic acid derivatives with antiviral activity |
| 07/30/2014 | EP2758411A2 Modified creatine compounds |
| 07/30/2014 | EP2758406A1 Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| 07/30/2014 | EP2758405A1 Novel antimicrobial compounds |
| 07/30/2014 | EP2758403A2 Tricyclic compounds useful as neurogenic and neuroprotective agents |
| 07/30/2014 | EP2758402A1 Pyrrolopyrimidine and purine derivatives |
| 07/30/2014 | EP2758401A1 Amino-substituted imidazopyridazines |
| 07/30/2014 | EP2758400A1 Substituted imidazopyridazines |
| 07/30/2014 | EP2758399A1 N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals |
| 07/30/2014 | EP2758398A1 Substituted n- [1-cyano-2- (phenyl) ethyl]-2-azabicyclo [2.2.1]heptane-3-carboxamide inhibitors of cathepsin c |
| 07/30/2014 | EP2758397A1 Imidazopyridine compounds, compositions and methods of use |
| 07/30/2014 | EP2758396A1 Triazolopyridine compounds as pde10a inhibitors |
| 07/30/2014 | EP2758395A1 Compounds useful as inhibitors of choline kinase |
| 07/30/2014 | EP2758394A1 Heteroaryl compounds as 5-ht4 receptor ligands |
| 07/30/2014 | EP2758393A1 N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors |
| 07/30/2014 | EP2758392A1 Use of strigolactones and strigolactone analogs for treating proliferative conditions |
| 07/30/2014 | EP2758389A1 Pyrazole carboxamides as janus kinase inhibitors |
| 07/30/2014 | EP2758388A1 New bicyclic dihydroquinoline-2-one derivatives |
| 07/30/2014 | EP2758387A1 Pyridine compounds as inhibitors of kinase |
| 07/30/2014 | EP2758384A1 Phenylimide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same |
| 07/30/2014 | EP2758383A1 Aromatic amidothiazoles, cosmetic or dermatological preparations containing said aromatic amidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin |
| 07/30/2014 | EP2758382A1 Heterocyclocarbonylaminothiazoles, cosmetic or dermatological preparations containing said heterocyclocarbonylaminothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin |
| 07/30/2014 | EP2758381A1 Alkylamidothiazoles, cosmetic or dermatological preparations containing said alkylamidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin |
| 07/30/2014 | EP2758380A1 Benzoic acid derivatives as eif4e inhibitors |
| 07/30/2014 | EP2758379A1 Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| 07/30/2014 | EP2758377A1 Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors |
| 07/30/2014 | EP2758375A1 Amide compounds, compositions and applications thereof |